flavonoids / COX2 Cancer Research Results

Flav, flavonoids: Click to Expand ⟱
Features:

Flavonoids — a large class of plant polyphenols (natural products) including flavonols (quercetin, kaempferol), flavones (apigenin, luteolin), flavanones (naringenin), isoflavones (genistein), flavan-3-ols (EGCG/catechins), and anthocyanins. Sources: fruits/berries, tea/cocoa, legumes, herbs, and standardized extracts.

Primary mechanisms (conceptual rank):
1) Redox signaling modulation (often hormetic: low-dose NRF2 ↑; high-dose ROS ↑ in cancer)
2) Anti-inflammatory transcription suppression (NF-κB ↓; cytokines ↓)
3) Kinase signaling modulation (PI3K/AKT/mTOR ↓; MAPK context-dependent)
4) Mitochondrial stress → apoptosis (cancer; often high concentration only)
5) Iron/copper chelation + lipid-peroxidation effects (ferroptosis overlap in select contexts)

Bioavailability / PK relevance: Many flavonoids have low oral bioavailability (rapid phase II conjugation: glucuronidation/sulfation; microbiome-derived metabolites). Plasma free aglycone levels are typically low; tissue effects often reflect metabolites and chronic exposure.

In-vitro vs oral exposure: Many “anti-cancer” cytotoxic effects occur at micromolar aglycone concentrations exceeding typical systemic exposure from diet/supplements (high concentration only), unless specialized formulations or local GI exposure is the intent.

Clinical evidence status: Broad epidemiology + small human trials for cardiometabolic/inflammatory endpoints; oncology evidence mostly preclinical/adjunct-hypothesis; no class-wide RCT oncology approval.


Flavonoids are classified into seven structural classes:
1.flavanones
-Nargenin, Naringin, Hesperetin, Isosakuranetin, Eriodictyol, Taxifolin
2.flavonols
-Quercetin, Myrcetin, Fisetin, Rutin Morin, Kaempferol
3.chalcones
-Butein, Xanthohumol, Isoliquintigenin, Cardamonin, Bavachalone, Xanthohumol, Phloretin
4.flavanols
-Catechin, Gallocatechin, Epicatechin, Epigallocatechin-3-galate
5.anthocyanidins
-Cyanidin
6.flavones
-Chrysin, Apigenin, Luteolin, Vitexin, Orientin, Bacalein, Wogonin, Oroxylin A, Saponarin
7.isoflavonoids
-Daidzein, Genistein, Glycitein


Flavonoids — a structurally diverse superfamily of plant-derived polyphenolic secondary metabolites characterized broadly by a C6–C3–C6 carbon framework. They are a phytochemical class rather than a single drug or uniform therapeutic modality. Standard abbreviations include flavonoids and Flav; individual subclasses require separate names. Major dietary subclasses are flavonols, flavones, flavanones, flavan-3-ols, anthocyanins and isoflavones; chalcones are also commonly included in the broader flavonoid family. Representative compounds include quercetin, kaempferol, fisetin, apigenin, luteolin, naringenin, hesperetin, catechin, epicatechin, EGCG, cyanidin, genistein and daidzein. Principal sources include fruits, berries, tea, cocoa, citrus, legumes, herbs and vegetables. Because flavonoids differ markedly in structure, metabolism and target selectivity, class-level statements describe recurring patterns rather than effects shared uniformly by every compound.

Primary mechanisms (ranked):

  1. Redox-signaling modulation, typically involving antioxidant and NRF2-linked cytoprotection at physiologic exposure but mitochondrial ROS elevation and oxidative injury in some cancer models at higher concentrations.
  2. Suppression of inflammatory transcriptional programs, particularly NF-κB-associated cytokine, COX-2 and inducible inflammatory signaling.
  3. Inhibition of proliferative and survival signaling through PI3K/AKT/mTOR, receptor tyrosine kinase, STAT3 and ERK pathways in compound-dependent cancer models.
  4. Induction of mitochondrial dysfunction, altered BCL-2-family balance, cytochrome-c release and caspase-mediated apoptosis.
  5. Cell-cycle arrest through modulation of cyclins, CDKs, p21, p27, p53 and related checkpoint machinery.
  6. Suppression of angiogenesis, epithelial–mesenchymal transition, invasion and metastasis through HIF-1α, VEGF, β-catenin, matrix metalloproteinase and adhesion-related pathways.
  7. Metabolic modulation involving glucose transport, glycolysis, HK2, PKM2, HIF-1α and AMPK signaling in selected compounds and models.
  8. Modulation of iron handling and lipid peroxidation; flavonoids may inhibit or promote ferroptosis depending on their chelating, radical-scavenging and pro-oxidant properties.
  9. Chemosensitization or radiosensitization through suppression of survival signaling, DNA-repair responses, drug-efflux mechanisms or antioxidant defenses in selected experimental systems.

Bioavailability / PK relevance: Oral pharmacokinetics vary substantially by subclass, glycosylation pattern, food matrix and intestinal microbiota. Most absorbed flavonoids undergo extensive intestinal and hepatic glucuronidation, sulfation and methylation, while unabsorbed material is converted by the microbiome into smaller phenolic metabolites. Circulating exposure therefore consists predominantly of conjugated and microbial metabolites rather than the free aglycones commonly used in laboratory experiments. Certain flavonoids can also affect drug transporters or CYP-mediated metabolism, but the clinical significance is compound-, dose- and medication-dependent.

In-vitro vs systemic exposure relevance: Many anticancer experiments use approximately 10–100 µM free aglycone, whereas normal dietary intake commonly produces much lower concentrations of unconjugated parent compound in plasma. Consequently, direct kinase inhibition, mitochondrial toxicity, apoptosis and ferroptosis observed at high micromolar concentrations may not be systemically achievable through ordinary foods or conventional supplements. Gastrointestinal tissues, concentrated formulations and pharmacologically developed derivatives may experience different exposure conditions.

Clinical evidence status: Human evidence is strongest for dietary patterns or standardized flavonoid-rich foods affecting vascular, cardiometabolic and selected cognitive endpoints. Cancer-prevention evidence is primarily observational and subclass-specific, while cancer-treatment evidence remains predominantly preclinical with limited early-phase or adjunct studies involving individual flavonoids. Flavonoids are not approved as a class for treating cancer or Alzheimer’s disease, and class-wide efficacy cannot be inferred from results obtained with one constituent.


Flavonoid Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Redox signaling and mitochondrial ROS ↑ or ↓ (dose-dependent) ↓ oxidative burden P R Hormetic redox modulation At physiologically relevant exposure, many flavonoids activate adaptive defenses or scavenge reactive species. High concentrations may instead produce mitochondrial ROS, glutathione depletion and cancer-cell injury.
2 NF-κB and inflammatory cytokines ↓ ↓ excessive inflammatory activation R G Anti-inflammatory transcriptional suppression A recurring class-level effect, although potency and direct molecular targets differ substantially among individual flavonoids.
3 PI3K AKT mTOR survival signaling ↓ (compound-dependent) ↔ or ↓ excessive signaling R G Reduced survival and anabolic signaling Commonly reported in cancer models but frequently demonstrated at concentrations above typical free systemic exposure.
4 Mitochondrial apoptosis ↑ ↔ or ↓ injury (dose-dependent) R G Caspase-dependent cell death May include mitochondrial depolarization, BAX activation, BCL-2 suppression, cytochrome-c release and caspase activation.
5 Cell-cycle checkpoints ↑ arrest and ↓ proliferation ↔ G Growth inhibition G1, S or G2/M arrest varies by flavonoid, tumor genotype and dose.
6 NRF2 antioxidant response ↑ or ↓ (context-dependent) ↑ R G Adaptive stress-defense regulation NRF2 activation can protect normal tissue but may also support survival and treatment resistance in NRF2-dependent cancers. Some flavonoids instead suppress pathological NRF2 signaling.
7 Angiogenesis and HIF-1α VEGF signaling ↓ (model-dependent) ↔ or improved endothelial function G Reduced tumor vascular adaptation Effects may arise through PI3K AKT mTOR inhibition, altered ROS signaling or direct suppression of HIF-1α and VEGF expression.
8 EMT invasion and metastasis ↓ ↔ G Reduced migratory and invasive phenotype Reported mechanisms include ↓ β-catenin, ZEB1, Snail, MMP2, MMP9 and focal-adhesion signaling, but effects are not uniform across the class.
9 Glycolysis and Warburg metabolism ↓ (compound-dependent) ↔ or improved metabolic regulation R G Reduced glucose-dependent tumor metabolism Selected flavonoids suppress GLUT1, HK2, PKM2, c-MYC or HIF-1α; direct inhibition is often observed at high concentration only.
10 MAPK stress signaling ↑ JNK and p38 or ↓ ERK (context-dependent) ↔ or adaptive modulation P R Stress-response and proliferation control Direction depends on the compound, basal pathway state and whether the dominant response is cytoprotection or apoptosis.
11 Ferroptosis and lipid peroxidation ↑ or ↓ (compound-dependent) Usually ↓ oxidative lipid injury R G Altered iron-dependent cell-death susceptibility Iron chelation and radical scavenging can inhibit ferroptosis, whereas pro-oxidant activity or suppression of antioxidant defenses can promote it.
12 Ca²⁺ and endoplasmic-reticulum stress ↑ stress signaling (model-dependent) ↔ or stabilized P R UPR and apoptosis modulation A secondary mechanism relevant to selected compounds rather than a uniform flavonoid-class effect.
13 Chemosensitization and radiosensitization ↑ treatment sensitivity (compound-dependent) ↔ or cytoprotection (context-dependent) R G Adjunct treatment modulation Experimental mechanisms include ↓ AKT, NF-κB, DNA repair, antioxidant defenses or drug-efflux activity. Antioxidant effects could be counterproductive in other treatment contexts.
14 Clinical Translation Constraint ↓ achievable pharmacologic effect Potential supplement interactions G PK and class heterogeneity Major constraints are extensive conjugation, metabolite-dominant exposure, low free-aglycone concentrations, nonstandardized preparations, subclass heterogeneity and limited oncology trials.

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr



Flavonoids and Alzheimer’s disease — dietary flavonoids and flavonoid-rich foods are investigated as supportive neurovascular and neuroprotective exposures rather than established Alzheimer’s disease therapies. The most defensible class-level mechanisms are attenuation of oxidative and inflammatory stress, enhancement of endothelial function and cerebral perfusion, and chronic modulation of synaptic-plasticity signaling. Effects on amyloid-β aggregation, amyloid processing, tau phosphorylation and clearance are primarily preclinical and vary markedly among compounds.

Primary mechanisms (ranked):

  1. Reduction of oxidative stress and lipid peroxidation through direct and metabolite-mediated redox effects and adaptive NRF2 signaling.
  2. Suppression of microglial and astrocytic inflammatory signaling, including NF-κB and pro-inflammatory cytokine programs.
  3. Support of cerebrovascular endothelial function, nitric-oxide signaling and neurovascular coupling.
  4. Enhancement of BDNF, CREB, ERK and related synaptic-plasticity pathways during sustained exposure.
  5. Preservation of mitochondrial function and cellular energy homeostasis.
  6. Secondary modulation of amyloid-β production, aggregation or toxicity and tau-associated signaling in selected preclinical models.

Bioavailability / PK relevance: Brain exposure is likely mediated largely by circulating conjugates, microbiome-derived phenolic metabolites and indirect vascular or peripheral signaling rather than sustained high concentrations of free parent flavonoids. Blood–brain barrier penetration differs considerably among compounds and metabolites.

Clinical evidence status: Observational cohorts associate higher flavonoid intake with slower cognitive decline or reduced dementia risk, and some randomized trials of cocoa flavanols, berries or anthocyanin-rich interventions report modest cognitive or vascular benefits. Results are heterogeneous, and biomarker-confirmed Alzheimer’s disease modification has not been established.


Alzheimer’s Disease Mechanistic Profile

Rank Pathway / Axis Modulation TSF Primary Effect Notes / Interpretation
1 Oxidative stress and lipid peroxidation ↓ P R Reduced neuronal oxidative injury Likely involves adaptive signaling and metabolites in addition to direct radical scavenging.
2 Neuroinflammation and NF-κB signaling ↓ R G Reduced inflammatory stress Reported in microglial, astrocytic and animal models; clinical confirmation remains limited.
3 NRF2 antioxidant response ↑ (context-dependent) R G Enhanced endogenous stress defense May increase antioxidant and detoxification enzymes; magnitude differs among flavonoids and metabolites.
4 Endothelial nitric oxide and cerebral perfusion ↑ R G Neurovascular support One of the more clinically plausible mechanisms, particularly for cocoa flavanols and anthocyanin-rich foods.
5 BDNF CREB and synaptic plasticity ↑ G Learning and memory support Strong preclinical rationale with limited but suggestive human cognitive evidence.
6 Mitochondrial function ↑ function and ↓ dysfunction R G Improved neuronal resilience Usually secondary to redox, inflammatory and kinase-signaling modulation.
7 Amyloid-β-associated pathology ↔ or ↓ (compound-dependent) G Reduced amyloid formation or toxicity Predominantly preclinical; class-wide disease-modifying activity should not be inferred.
8 Tau phosphorylation and aggregation ↔ or ↓ (compound-dependent) G Reduced tau-associated dysfunction Evidence is mechanistically plausible but remains mainly cellular or animal-based.
9 Ca²⁺ homeostasis and excitotoxicity ↔ or stabilized P R Reduced excitotoxic vulnerability An indirect and secondary class-level mechanism rather than a universal direct calcium-channel effect.
10 Clinical Translation Constraint ↓ certainty of therapeutic effect G Heterogeneity and metabolite dependence Trials differ in subclass, food matrix, dose, duration, cognitive population and outcome measures; Alzheimer’s disease modification is unproven.

TSF: P: 0–30 min    R: 30 min–3 hr    G: >3 hr
COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals.
-Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis.
-COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors.

COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers.
The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression:
Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways.
Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer.
Drugs specifically targeting COX-2, such as celecoxib, have been developed.

COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS.
Scientific Papers found: Click to Expand⟱
6923- Flav,    Flavonoids: an overview
- Review, Nor, NA
*antiOx↑, AntiCan↑, *cardioP↑, *XO↓, *COX2↓, *5LO↓, *PI3K↓, *AChE↓, *Imm⇅, *BP↓, TumCCA↑, *Aβ↓, *BACE↓, *NF-kB↓, *ROS↓, *neuroP↑, *AntiAg↑, *AntiThr↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,  
Total Targets: 2

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ROS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PI3K↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   AntiAg↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   Imm⇅, 1,   NF-kB↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   BACE↓, 1,   XO↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BP↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   neuroP↑, 1,  
Total Targets: 16

Scientific Paper Hit Count for: COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:227  Target#:66  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page